Aulos Bioscience Doses First Patient in Phase II Cohort Evaluating AU-007 in Combination With Nivolumab for Second-Line Treatment of Melanoma

Aulos Bioscience aannounced dosing of its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma.